Pienta Kenneth 4
4 · Cue Biopharma, Inc. · Filed Mar 17, 2021
Insider Transaction Report
Form 4
Pienta Kenneth
Chief Medical Officer
Transactions
- Exercise/Conversion
Common Stock
2021-03-15$5.00/sh+13,000$65,000→ 15,000 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-16−439→ 133,567 totalExercise: $5.00Exp: 2024-04-17→ Common Stock (439 underlying) - Sale
Common Stock
2021-03-16$15.09/sh−439$6,626→ 2,000 total - Sale
Common Stock
2021-03-15$15.10/sh−13,000$196,269→ 2,000 total - Exercise/Conversion
Stock Option (right to buy)
2021-03-15−13,000→ 134,006 totalExercise: $5.00Exp: 2024-04-17→ Common Stock (13,000 underlying) - Exercise/Conversion
Common Stock
2021-03-16$5.00/sh+439$2,195→ 2,439 total
Footnotes (4)
- [F1]The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2020.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.72, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (2) to this Form 4.
- [F3]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.05 to $15.22, inclusive. The reporting person undertakes to provide to Cue Biopharma, Inc., any security holder of Cue Biopharma, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth in this footnote (3) to this Form 4.
- [F4]The option, representing a right to purchase a total of 150,000 shares, vests in four equal annual installments beginning December 31, 2017.